Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.42 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | PLAU | P00749 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3367559 | 0.83 | PRNP (0.38) | KDM4EHPGD | |
| SCHEMBL18496493 | 0.81 | HRH4 (0.37) | KDM4ECYP2C9LMNA | |
| SCHEMBL20604803 | 0.81 | GRM2 (0.42) | ALDH1A1KDM4EHPGDHSD17B10SMN1; SMN2 | |
| SCHEMBL8296174 | 0.79 | ALDH1A1 (0.43) | ALDH1A1KDM4EHPGDHSD17B10PABPC1 | |
| SCHEMBL20604737 | 0.78 | CYP1A2 (0.40) | ALDH1A1KDM4EHPGDHSD17B10PABPC1 | |
| SCHEMBL3364428 | 0.77 | GABRG2 (0.41) | ALDH1A1KDM4EHPGDHSD17B10PABPC1 | |
| SCHEMBL1562180 | 0.76 | ALDH1A1 (0.49) | ALDH1A1KDM4EHPGDHSD17B10PABPC1 | |
| SCHEMBL3364407 | 0.76 | HSD17B10 (0.44) | ALDH1A1HPGDHSD17B10SMN1; SMN2F2 | |
| SCHEMBL3364253 | 0.75 | NR4A2 (0.41) | ALDH1A1KDM4EHPGDHSD17B10PABPC1 | |
| SCHEMBL3364683 | 0.75 | TP53 (0.40) | ALDH1A1KDM4EHPGDHSD17B10PABPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2024-11-19 | — | — | US | disclosed |
| WO-2024099269-A1 | ARYLAMIDE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, USE THEREOF | 华东师范大学 | 2024-05-16 | — | — | WO | disclosed |
| CN-118026880-A | Aryl amide compound, pharmaceutical composition containing same and application thereof | 华东师范大学 | 2024-05-14 | — | — | CN | disclosed |
| EP-4292662-A2 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | Vanderbilt University (US) | 2023-12-20 | — | — | EP | disclosed |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2023-10-19 | — | — | US | disclosed |
| EP-3423435-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2023-03-07 | — | — | US | disclosed |
| CN-109153643-B | Substituted indole MCL-1 inhibitors | 范德比尔特大学 | 2022-06-21 | — | — | CN | disclosed |
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2021-09-16 | — | — | US | disclosed |
| CN-107922380-B | Microbicidal heterobicyclic derivatives | 先正达参股股份有限公司 | 2021-07-09 | — | — | CN | disclosed |
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | COURNOYER RICHARD L | 2007-09-13 | — | — | US | disclosed |
| US-7214699-B2 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214699-B2 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214699-B2 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1656353-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-17 | — | — | EP | disclosed |
| EP-1569911-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-07 | — | — | EP | disclosed |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | ROCHE PALO ALTO LLC | 2005-05-12 | — | — | US | disclosed |
| WO-2005016892-A1 | GABANERGIC MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004050634-A1 | INDAZOLE DERIVATIVES AS CRF ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-17 | — | — | WO | disclosed |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | ROCHE PALO ALTO LLC | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210283138-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | ALDH1A1 2556/4885KDM4E 1156/4885HPGD 3190/4885 |
| US-20070213373-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, CRH | ALDH1A1 1289/4885KDM4E 4580/4885HPGD 1080/4885 |
| US-20040110815-A1 | Indazole derivatives as CRF antagonists | CRHR1, CRHR2, ARRB1 | ALDH1A1 1266/4885KDM4E 4580/4885HPGD 1058/4885 |
| US-20050101614-A1 | For example, 7-(2,4-Dichloro-phenyl)-2-methyl-2H-pyrazolo[4,3-b]pyridine; for treatment of depression, an anxiety disorder, a psychiatric disorder, a learning or cognitive disorder, a sleep disorder, a convulsive or seizure disorder, or pain | HTR2C, GABRA2, GABRA4 | ALDH1A1 536/4885KDM4E 449/4885HPGD 719/4885 |
| US-12144816-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | ALDH1A1 2556/4885KDM4E 1156/4885HPGD 3190/4885 |
| US-20230330099-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2L1, BCL9 | ALDH1A1 2556/4885KDM4E 1156/4885HPGD 3190/4885 |
| US-11596639-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2L1, BCL9 | ALDH1A1 2556/4885KDM4E 1156/4885HPGD 3190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.